Preclinical testing provided evidence that ebselen is safe and tolerable, and it has shown no significant adverse effects in ensuing clinical trials.
Not exact matches
Based on these
preclinical findings, CRI
provides a seed grant for a phase I clinical trial to
test the strategy in patients with metastatic renal cell carcinoma.
CRI
provides a pilot grant to Jean - Pierre Mach for
preclinical studies to
test a new cancer immunotherapy strategy using anti-tumor antibody fragments conjugated to antigenic MHC / peptide complexes.
This model offers unique capabilities for
preclinical assessment of thrombosis risk in a patient - specific manner, including efficacy
testing of anti-thrombotic agents, elucidation of mechanism of action, and, potentially, biomarker identification, all
providing a much - needed platform for drug discovery and development.
«Not only does this research
provide compelling evidence for further investigation of immunotherapy for treating stomach cancer, it also
provides the first model for
preclinical testing of these treatments.»
The goal of this Center of Excellence is to better define thrombus development in patients with cancer,
test the efficacy of novel therapies, develop new
preclinical models, and create and expand biorepositories to
provide a valuable resource to researchers across Cleveland Clinic.